Zoledronic acid

(HB0674)

Certificate of Analysis

Latest Certificate of Analysis

Download the latest CoA for this product:

Download CoA

Download Batch-Specific CoA

To download the CoA for a batch, enter the batch ID below:

Technical documents: CoA Datasheet

Product overview

Name Zoledronic acid
Alternative names Zometa
Description Highly potent bisphosphonate, shows variety of biological actions
Write Your Own Review
You're reviewing:Zoledronic acid
Rate this item:

Biological Data

Biological description

Highly potent bisphosphonate, shows variety of biological actions. Ras signaling inhibitor. Inhibits bone metastasis. Shows apoptotic effects and inhibits proliferation. Also reduces tumour burden and growth.

Solubility & Handling

Storage of solutions Prepare and use solutions on the same day if possible. Store solutions at -20°C for up to one month if storage is required. Equilibrate to RT and ensure the solution is precipitate free before use.
Shipping Conditions Stable for ambient temperature shipping. Follow storage instructions on receipt.
Important This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use.

Calculators

Molarity

=
x
x
More Info

Dilution

x
=
x
More Info

Chemical Data

Chemical name Zoledronate
Molecular Weight 272.09
Chemical structure Zoledronic acid  [118072-93-8] Chemical Structure
Molecular Formula C5H10N2O7P2
CAS Number 118072-93-8
PubChem identifier 68740
SMILES C1=CN(C=N1)CC(O)(P(=O)(O)O)P(=O)(O)O
InChiKey XRASPMIURGNCCH-UHFFFAOYSA-N

References for Zoledronic acid

References are publications that support the biological activity of the product
  • Zoledronic acid affects the cytotoxic effects of Chlamydia pneumoniae and the modulation of cytokine production in human osteosarcoma cells.

    Rizzo A et al (2014) Int Immunopharmacol 22(1) : 66-72.
  • Zoledronic acid inhibits macrophage/microglia-assisted breast cancer cell invasion.

    Rietkötter E et al (2013) Oncotarget 4(9) : 1449-60.
  • Antineoplastic activity of zoledronic acid and denosumab.

    Zwolak P et al (2013) Anticancer Res 33(8) : 2981-8.

3 Item(s)